Author(s): Zacher M, Heppt MV, Brinker TJ, Hayani KM, Flaig MJ, et al.
Sarcomas are a heterogeneous group of mesenchymal tumors which can affect bone and soft tissue. Leiomyosarcoma (LMS) is a rare subtype localized to the skin or subcutaneous tissue. Due to the heterogeneity of sarcomas, reviews and guidelines with an in-depth focus specifically on primary LMS of the skin are sparse. This article is intended to provide an up to date and systematic overview on diagnosis, treatment, and surveillance of this rare entity to provide a framework for decision making and management for dermato-oncologists. We discuss novel treatment options for advanced disease such as targeted therapy with kinase inhibitors and immune checkpoint blockade which may improve the prognosis even in advanced stages of LMS.
Referred From: https://link.springer.com/article/10.1007/s12032-018-1196-2
Author(s): Hung GY, Horng JL, Chen PC
Author(s): Mayerhofer K, Obermair A, Windbichler G
Author(s): Bharambe BM, Deshpande KA, Surase SG, Ajmera AP
Author(s): Rotmensch J, Bosnyak S, Montag A
Author(s): Yanai H, Wani Y, Notohara K, Takada S, Yoshino T
Author(s): Winchester DS, Hocker TL, Brewer JD
Author(s): Fields JP, Helwig EB
Author(s): Bernstein SC, Roenigk RK
Author(s): Choi JH, Ro JY
Author(s): Starr GF, Dockerty MB
Author(s): Humphreys TR, Finkelstein DH, Lee JB
Author(s): Rao UN, Finkelstein SD, Jones MW
Author(s): Starling J, Coldiron BM
Author(s): Liao WC, Wang YC, Ma H
Author(s): Svarvar C, Bohling T, Berlin O